journal
https://read.qxmd.com/read/39367998/adverse-event-profile-of-first-line-drugs-for-treating-patent-ductus-arteriosus-in-neonates-a-disproportionality-analysis-study-of-usfda-adverse-event-reporting-system
#1
JOURNAL ARTICLE
Kannan Sridharan, Gowri Sivaramakrishnan
BACKGROUND: Acetaminophen, ibuprofen, and indomethacin are widely used as first-line drugs for patent ductus arteriosus (PDA) closure in preterm neonates. However, their relative safety profiles remain unclear. METHODS: Adverse event reports related to the first-line drugs used in PDA and neonates in general were retrieved from the US Food and Drug Authority (FDA) Adverse Event Reporting System. Deduplicated reports were analyzed using proportional reporting ratios and reporting odds ratios to identify disproportionality safety signals between drugs...
October 5, 2024: Paediatric Drugs
https://read.qxmd.com/read/39333447/a-narrative-review-of-pain-in-pediatric-oncology-the-opioid-option-for-procedural-and-surgical-pain
#2
REVIEW
Elizabeth A Hall, Chasity M Shelton, Tracy M Hagemann, Hilary M Jasmin, Karissa Grey, Doralina L Anghelescu
This narrative review examines the evolving role of opioids in managing procedural and surgical pain in pediatric oncology patients. The review evaluates studies on opioid use across various oncological surgeries including thoracic, abdominal, orthopedic, and neurosurgical procedures, as well as for common painful procedures such as bone marrow aspirations and lumbar punctures. While opioids remain important for acute procedural and postoperative pain management in pediatric oncology patients, there is an increasing emphasis on multimodal, opioid-sparing approaches...
September 28, 2024: Paediatric Drugs
https://read.qxmd.com/read/39331340/the-effect-of-levetiracetam-and-valproic-acid-treatment-on-anger-and-attention-deficit-hyperactivity-disorder-clinical-features-in-children-and-adolescents-with-epilepsy-a-prospective-study
#3
JOURNAL ARTICLE
Zeynep Vatansever Pınar, Safiye Güneş Sağer, İrem Damla Çimen, Yakup Çağ
BACKGROUND AND OBJECTIVE: Antiseizure medications (ASMs) can potentially trigger psychobehavioral adverse events associated with the onset or exacerbation of psychiatric symptoms such as irritability, aggression, and hyperactivity. The objective of this study was to evaluate the effects of levetiracetam and valproic acid on changes in clinical features of anger, attention deficit hyperactivity disorder (ADHD), and oppositional defiant disorder (ODD). The purpose was to furnish guidance on rational drug selection in children and adolescents with epilepsy to minimize psychiatric comorbidity in the treatment of epilepsy...
September 27, 2024: Paediatric Drugs
https://read.qxmd.com/read/39331339/efficacy-and-safety-of-vamorolone-in-duchenne-muscular-dystrophy-a-systematic-review
#4
JOURNAL ARTICLE
Carlos Pascual-Morena, Maribel Lucerón-Lucas-Torres, Irene Martínez-García, Eva Rodríguez-Gutiérrez, Silvana Patiño-Cardona, Irene Sequí-Domínguez
BACKGROUND: Vamorolone has recently been approved for the management of Duchenne muscular dystrophy to replace glucocorticosteroids, which theoretically have more side effects. However, its efficacy and safety profile is unclear. OBJECTIVE: We aimed to assess the efficacy of vamorolone in Duchenne muscular dystrophy through the 6-minute walk test (6MWT), the North Star Ambulatory Assessment (NSAA), time to stand velocity (TTSTAND), time to run 10 m (TTRW), time to climb four stairs (TTCLIMB) and a safety profile...
September 27, 2024: Paediatric Drugs
https://read.qxmd.com/read/39325135/recent-developments-in-the-treatment-of-pediatric-distal-renal-tubular-acidosis
#5
JOURNAL ARTICLE
Olivia Boyer, Mélissa Ould Rabah, Evgenia Preka
Distal renal tubular acidosis (dRTA) is characterized by a primary defect in proton secretion by α-intercalated cells of the collecting duct, leading to impaired urine acidification and resulting in metabolic acidosis, hypokalemia, and hypercalciuria. Inherited forms of dRTA are currently associated with variants in five genes (SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, and WDR72), each being associated with specific extra-renal manifestations. Acquired forms can result from autoimmune diseases or drug side effects...
September 26, 2024: Paediatric Drugs
https://read.qxmd.com/read/39251556/role-of-mtor-inhibitors-in-pediatric-liver-transplant-recipients-a-systematic-review
#6
JOURNAL ARTICLE
Marjan Moghadamnia, Simin Dashti-Khavidaki, Hosein Alimadadi
BACKGROUND: Immunosuppressive medications play a crucial role in determining both organ and patient survival following liver transplantation (LT). Typically, immunosuppressive protocols for pediatric LT patients rely on calcineurin inhibitors (CNIs). While inhibitors of mammalian target of rapamycin (mTOR) have demonstrated beneficial outcomes in adult recipients of liver allografts, such as improved renal function post-LT, their application in pediatric liver transplant recipients is a subject of debate due to uncertain efficacy and potential adverse effects...
September 9, 2024: Paediatric Drugs
https://read.qxmd.com/read/39215954/preventing-recurrence-of-crohn-s-disease-post-ileocaecal-surgery-in-paediatric-patients-a-therapy-guide-based-on-systematic-review-of-the-evidence
#7
JOURNAL ARTICLE
Jiri Bronsky, Kristyna Zarubova, Michal Kubat, Vojtech Dotlacil
BACKGROUND AND AIMS: Ileocaecal resection (ICR) is frequent in paediatric patients with Crohn's disease (pCD). Despite rates of reoperation being low, the risk of clinical or endoscopic post-operative recurrence (POR) is high; effective medical strategies to prevent POR are thus needed. The aim of this systematic review (SR) was to identify and evaluate the published literature on post-operative medical prevention of POR in pCD to draft a possible therapy guide for pCD patients undergoing ICR...
August 31, 2024: Paediatric Drugs
https://read.qxmd.com/read/39198371/targeted-treatments-for-myasthenia-gravis-in-children-and-adolescents
#8
REVIEW
Sithara Ramdas, Teresa Painho, Maria I Vanegas, Dennis T Famili, Ming J Lim, Heinz Jungbluth
Myasthenia gravis (MG) is an antibody-mediated disorder of the neuromuscular junction affecting children and adults. MG is a treatable condition with most patients requiring immunosuppression for disease control and/or remission. Juvenile myasthenia gravis (JMG) is rare in comparison with adult-onset MG but given the same underlying pathophysiology, treatment strategies are similar to those in adults. Until recently, there were only a few randomised controlled trials (RCTs) for MG treatments in adults and none in children, and management strategies were primarily based on expert consensus...
August 28, 2024: Paediatric Drugs
https://read.qxmd.com/read/39192168/%C3%A2-pediatric-chronic-inflammatory-demyelinating-polyneuropathy-challenges-in-diagnosis-and%C3%A2-therapeutic-strategies
#9
REVIEW
Issa Alawneh, Asmaa Alenizi, Freddy Paiz, Elisa Nigro, Jiri Vajsar, Hernan Gonorazky
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune neurological disorder seen in both pediatric and adult populations. CIDP typically presents with progressive and persistent weakness over at least 4 weeks in addition to sensory symptoms in the extremities. Although CIDP shares common clinical features between children and adults, it sometimes presents as a distinct clinical entity in children that requires close attention and recognition. A major caveat when diagnosing a child with CIDP is the clinical and diagnostic overlap with inherited neuropathies, most commonly Charcot-Marie-Tooth disease (CMT)...
August 27, 2024: Paediatric Drugs
https://read.qxmd.com/read/39112827/comparison-of-different-doses-of-oral-and-ocular-propranolol-for-retinopathy-of-prematurity-a-network-meta-analysis
#10
JOURNAL ARTICLE
Amparo Ortiz-Seller, Pablo Martorell, Patricia Roselló, Esteban Morcillo, José L Ortiz
OBJECTIVE: The efficacy and safety of propranolol for retinopathy of prematurity (ROP) remain under debate. This network meta-analysis (NMA) focuses on whether a ranking may be established for different dose levels of propranolol as treatment of ROP in terms of stage progression as the primary outcome, with appearance of plus disease and need for anti-vascular endothelial growth factors (anti-VEGFs) or laser therapy as secondary endpoints. METHODS: Fourteen studies (10 randomised controlled trials, three single-arm trials and one retrospective observational study) of 474 patients treated with oral or ocular propranolol were retrieved from databases up to April 2024...
August 7, 2024: Paediatric Drugs
https://read.qxmd.com/read/39102172/clinical-evidence-supporting-fda-approval-of-gene-and-rna-therapies-for-rare-inherited-conditions
#11
JOURNAL ARTICLE
Ilina C Odouard, Jeromie Ballreich, Branden Lee, Mariana P Socal
BACKGROUND: Gene and RNA therapies have potential to transform the treatment of rare inherited diseases, but there are concerns about the evidence supporting their use and high costs. OBJECTIVE: We analyze the evidence supporting Food and Drug Administration (FDA) approval of gene and RNA therapies for rare inherited diseases and discuss implications for clinical practice and policy. METHODS: We conducted a qualitative analysis of FDA documents outlining the basis of approval for gene and RNA therapies approved for rare inherited diseases between 2016 and 2023...
August 5, 2024: Paediatric Drugs
https://read.qxmd.com/read/39044097/methotrexate-intolerance-in-juvenile-idiopathic-arthritis-definition-risks-and-management
#12
JOURNAL ARTICLE
Camilla Wibrand, Nini Kyvsgaard, Troels Herlin, Mia Glerup
Juvenile idiopathic arthritis is the most common rheumatic disorder in childhood and adolescence posing a significant threat of short-term and long-term disability if left untreated. Methotrexate is a folic acid analog with various immunomodulatory properties. It has demonstrated significant efficacy for the treatment of juvenile idiopathic arthritis, often considered the preferred first-line disease-modifying anti-rheumatic drug given as monotherapy or in combination with biological drugs. Despite this, there is a considerable risk for treatment disruptions owing to the high prevalence of methotrexate intolerance, with symptoms such as nausea, stomach ache, vomiting, and behavioral symptoms...
July 24, 2024: Paediatric Drugs
https://read.qxmd.com/read/39044096/adverse-drug-reactions-in-children-with-congenital-heart-disease-a-scoping-review
#13
JOURNAL ARTICLE
Esmaeel Toni, Haleh Ayatollahi, Reza Abbaszadeh, Alireza Fotuhi Siahpirani
BACKGROUND: Congenital heart disease (CHD) is one of the leading causes of death. Safe and timely medical interventions, especially in children, can prolong their survival. The drugs prescribed for children with CHD are mainly based on the outcomes of drug therapy in adults with cardiovascular diseases, and their adverse drug reactions (ADRs) might be different. Therefore, the aim of this study was to investigate ADRs in children with CHD. METHODS: This was a scoping review conducted in 2023...
July 23, 2024: Paediatric Drugs
https://read.qxmd.com/read/38780740/effectiveness-and-safety-of-ustekinumab-in-pediatric-ulcerative-colitis-a-multi-center-retrospective-study-from-the-pediatric-ibd-porto-group-of-espghan
#14
MULTICENTER STUDY
Shlomi Cohen, Helena Rolandsdotter, Kaija-Leena Kolho, Dan Turner, Christos Tzivinikos, Matteo Bramuzzo, Gemma Pujol-Muncunill, Luca Scarallo, Darja Urlep, Firas Rinawi, Maya Granot, Ben Kang, Ylva Longueville, Marta Velasco Rodríguez-Belvís, Yael Weintraub, Víctor Manuel Navas-López, Anat Yerushalmy-Feler
BACKGROUND AND OBJECTIVES: Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety of ustekinumab in pediatric UC and IBDU. METHODS: This multicenter retrospective study included 16 centers affiliated with the IBD Interest and Porto groups of ESPGHAN. Children with UC or IBDU treated with ustekinumab were enrolled. Demographic, clinical, laboratory, endoscopic, and imaging data as well as adverse events were recorded...
September 2024: Paediatric Drugs
https://read.qxmd.com/read/38963501/drug-drug-interactions-involving-high-alert-medications-that-lead-to-interaction-associated-symptoms-in-pediatric-intensive-care-patients-a-retrospective-study
#15
JOURNAL ARTICLE
Lisa Marie Kiesel, Astrid Bertsche, Wieland Kiess, Manuela Siekmeyer, Thilo Bertsche, Martina Patrizia Neininger
BACKGROUND: Children treated in a pediatric intensive care unit (PICU) often receive several drugs together, among them drugs defined as high-alert medications (HAMs). Those drugs carry a high risk of causing patient harm, for example, due to a higher potential for interactions. HAMs should therefore be administered with caution, especially in a PICU. OBJECTIVES: The objective of the current study was to identify drug-drug interactions involving HAMs that increase the risk of interaction-associated symptoms in pediatric intensive care...
July 4, 2024: Paediatric Drugs
https://read.qxmd.com/read/38954225/a-narrative-review-of-pain-in-pediatric-oncology-the-opioid-option
#16
REVIEW
Elizabeth A Hall, Tracy M Hagemann, Chasity M Shelton, Hilary M Jasmin, Alexis N Calvasina, Doralina L Anghelescu
Opioid therapy is the mainstay for managing pain in pediatric oncology. This narrative review describes the current literature regarding opioids for pediatric cancer pain. The review explores the multifaceted landscape of opioid utilization in this population, including the role of opioids in certain clinical circumstances, modalities of opioid delivery, unique opioids, outpatient and at-home pain management strategies, and other key concepts such as breakthrough pain. This review highlights the importance of individualized dosing and multimodal approaches to enhance efficacy and minimize adverse effects...
July 2, 2024: Paediatric Drugs
https://read.qxmd.com/read/38877303/pediatric-treatment-resistant-obsessive-compulsive-disorder-treatment-options-and-challenges
#17
REVIEW
Sana Younus, Lauren Havel, Jordan T Stiede, Catherine E Rast, Kirti Saxena, Wayne K Goodman, Eric A Storch
Pediatric obsessive-compulsive disorder (OCD) is a chronic, potentially debilitating psychiatric condition. Although effective treatments exist, at least 10% of youth do not achieve remission despite receiving first-line treatments. This article reviews the extant, albeit limited, evidence supporting treatment approaches for youth with treatment-resistant OCD. A literature search for articles addressing pediatric treatment-resistant OCD was conducted through April 11, 2024. These results were augmented by searching for treatment-resistant OCD in adults; treatment strategies discovered for the adult population were then searched in the context of children and adolescents...
July 2024: Paediatric Drugs
https://read.qxmd.com/read/38805115/diagnosis-and-management-of-pediatric-neuropsychiatric-systemic-lupus-erythematosus-an-update
#18
REVIEW
Dilara Unal, Veysel Cam, Hulya Ercan Emreol, Seza Özen
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a potentially serious and life-threatening complication of SLE. The presentation and severity of neuropsychiatric involvement in SLE may show considerable variability. The disease can affect the neural tissue directly or may be associated with vascular involvement, mainly associated with anti-phospholipid (aPL) antibodies. A direct causal link with SLE may sometimes be challenging since there are many confounding factors and the symptoms may be non-specific...
July 2024: Paediatric Drugs
https://read.qxmd.com/read/38937427/commercial-versus-compounded-preparations-in-pediatric-ophthalmology
#19
JOURNAL ARTICLE
Annegret Dahlmann-Noor, Jill Bloom, Saw Keng Lee, Samiya Chowdhury, Kanwal Nischal, Dominique Bremond-Gignac
Many conditions managed by pediatric ophthalmologists are rare diseases, and even if pharmacological treatments are available, these have often not been evaluated in children. Off-label prescribing is a common practice in pediatric ophthalmology. In addition, there is often no commercial case for the production of a medicine that may only be used for a small number of patients worldwide. Compounded preparations prepared locally are therefore still in frequent use, although it is known that production may not meet stringent quality assurance standards...
June 27, 2024: Paediatric Drugs
https://read.qxmd.com/read/38880837/machine-learning-a-potential-therapeutic-tool-to-facilitate-neonatal-therapeutic-decision-making
#20
JOURNAL ARTICLE
Bo-Hao Tang, Qiu-Yue Li, Hui-Xin Liu, Yi Zheng, Yue-E Wu, John van den Anker, Guo-Xiang Hao, Wei Zhao
Bacterial infection is one of the major causes of neonatal morbidity and mortality worldwide. Finding rapid and reliable methods for early recognition and diagnosis of bacterial infections and early individualization of antibacterial drug administration are essential to eradicate these infections and prevent serious complications. However, this is often difficult to perform due to non-specific clinical presentations, low accuracy of current diagnostic methods, and limited knowledge of neonatal pharmacokinetics...
June 16, 2024: Paediatric Drugs
journal
journal
34607
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.